| Ms Delphine Sitsofe Ayivor, | |
|
9264 Garrett Lake Dr, Midland, GA 31820-4446 | |
| (732) 687-2012 | |
| Not Available |
| Full Name | Ms Delphine Sitsofe Ayivor |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 9264 Garrett Lake Dr, Midland, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295277754 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | RN212661 (Georgia) | Primary |
| 364SC2300X | Clinical Nurse Specialist - Chronic Care | RN212661 (Georgia) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Delphine Sitsofe Ayivor, 9264 Garrett Lake Dr, Midland, GA 31820-4446 Ph: (732) 687-2012 | Ms Delphine Sitsofe Ayivor, 9264 Garrett Lake Dr, Midland, GA 31820-4446 Ph: (732) 687-2012 |
News Archive
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.
Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal.
Bionovo, Inc. today announced that on March 16, 2010, the Company received a letter from NASDAQ stating that the Company has been granted an additional 180 day grace period, until September 13, 2010, to regain compliance with the minimum bid price of $1.00 required for continued listing on the NASDAQ Capital Market.
› Verified 3 days ago